Age-related differential sensitivity to MK-801-induced locomotion and stereotypy in C57BL/6 mice

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 161-168

  Qi, Chunting ^a   Zou, Hong ^a   Zhang, Ruizhong ^a   Zhao, Guoping ^a   Jin, Meilei ^a   Yu, Lei ^b  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Aging; Differential drug sensitivity; Dizocilpine maleate; Locomotion; Noncompetitive NMDA receptor antagonist; Stereotypy

Indexed keywords

DIZOCILPINE MALEATE;

AGED; AGING; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIMENTAL MODEL; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STEREOTYPY;

AGE FACTORS; AGING; ANIMALS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; STEREOTYPED BEHAVIOR;

EID: 37648999024     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.07.071     Document Type: Article

References (35)

1. Adriani W., Felici A., Sargolini F., Roullet P., Usiello A., Oliverio A., and Mele A. N-methyl-d-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp. Brain Res. 123 (1998) 52-59
2. Carlsson M., and Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75 (1989) 221-226
3. Carlsson M., and Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends NeuroSci. 13 (1990) 272-276
4. Carlsson A., Waters N., and Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry 46 (1999) 1388-1395
5. Clineschmidt B.V., Martin G.E., Bunting P.R., and Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [D]cyclohepten-5, 10-immine(MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res. 2 (1982) 135-145
6. Costall B., and Naylor R.J. The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur. J. Pharmacol. 32 (1975) 87-92
7. Costall B., and Naylor R.J. Dissociation of stereotyped biting responses and oro-bucco-lingual dyskinesias. Eur. J. Pharmacol. 36 (1976) 423-429
8. Costall B., Naylor R.J., and Neumeyer J.L. Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur. J. Pharmacol. 31 (1975) 1-16
9. Deutsch S.I., Rosse R.B., and Mastropaolo J. Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clin. Neuropharmacol. 20 (1997) 375-384
10. Frantz K., and Van Hartesveldt C. Locomotion elicited by MK801 in developing and adult rats: temporal, environmental, and gender effects. Eur. J. Pharmacol. 369 (1999) 145-157
11. Haggerty G.C., and Brown G. Neurobehavioral profile of subcutaneously administered MK-801 in the rat. Neurotoxicology 17 (1996) 913-921
12. Institute of Laboratory Animal Resources. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington, D.C.
13. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatr. 9 (1987) 12-35
14. Kelly P.H., Seviour P.W., and Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94 (1975) 507-522
15. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20 (1980) 379-382
16. Kuczenski R., and Segal D.S. Sensitization of amphetamine-induced stereotyped behaviors during the acute response. J. Pharmacol. Exp. Ther. 288 (1999) 699-709
17. Loscher W., and Honack D. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215 (1992) 199-208
18. Magnusson K.R. Differential effects of aging on binding sites of the activated NMDA receptor complex in mice. Mech. Ageing Dev. 84 (1995) 227-243
19. Magnusson K.R., Nelson S.E., and Young A.B. Age-related changes in the protein expression of subunits of the NMDA receptor. Brain Res. Mol. Brain Res. 99 (2002) 40-45
20. Mitchell J.J., and Anderson K.J. Age-related changes in [3H]MK-801 binding in the Fischer 344 rat brain. Neurobiol. Aging 19 (1998) 259-265
21. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
22. Nishith P., Griffin M.G., and Poth T.L. Stress-induced analgesia: prediction of posttraumatic stress symptoms in battered versus nonbattered women. Biol. Psychiatry 51 (2002) 867-874
23. O'Neill M.F., and Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacol. 145 (1999) 237-250
24. Ossowska K., Wolfarth S., Schulze G., Wardas J., Pietraszek M., Lorenc-Koci E., Smialowska M., and Coper H. Decline in motor functions in aging is related to the loss of NMDA receptors. Brain Res. 907 (2001) 71-83
25. Rujescu D., Bender A., Keck M., Hartmann A.M., Ohl F., Raeder H., Giegling I., Genius J., McCarley R.W., Moller H.J., and Grunze H. A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59 (2006) 721-729
26. Rung J.P., Carlsson A., Ryden M.K., and Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 29 (2005) 827-832
27. Schiffelholz T., Hinze-Selch D., and Aldenhoff J.B. Perinatal MK-801 treatment affects age-related changes in locomotor activity from childhood to later adulthood in rats. Neurosci. Lett. 360 (2004) 157-160
28. Segal D.S., and Kuczenski R. Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J. Pharmacol. Exp. Ther. 242 (1987) 917-926
29. Suzuki Y., Takagi Y., Nakamura R., Hashimoto K., and Umemura K. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats. Brain Res. 964 (2003) 116-120
30. Thornberg S.A., and Saklad S.R. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 16 (1996) 82-93
31. Tiedtke P.I., Bischoff C., and Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. Gen. Sect. 81 (1990) 173-182
32. Tricklebank M.D., Singh L., Oles R.J., Preston C., and Iversen S.D. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167 (1989) 127-135
33. Vasilev V., Veskov R., Janac B., Rakic L., and Stojiljkovic M. Age-related differences in MK-801-and amphetamine-induced locomotor and stereotypic activities of rats. Neurobiol. Aging 24 (2003) 715-723
34. Villares J.C., and Stavale J.N. Age-related changes in the N-methyl-d-aspartate receptor binding sites within the human basal ganglia. Exp. Neurol. 171 (2001) 391-404
35. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., Zhao G., Jin M., and Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacol. 177 (2005) 256-263